Literature DB >> 3404163

Effect of bromocriptine and metoclopramide on serum prolactin levels in patients with amyotrophic lateral sclerosis.

J Szulc-Kuberska1, H Stepień, A Klimek, D Cieślak.   

Abstract

Secretion of prolactin in nine patients with amyotrophic lateral sclerosis and in seven healthy men was investigated with the use of metoclopramide stimulation and bromocriptine inhibition tests. Blood serum prolactin concentration was determined in the basal state and 30, 60 and 120 minutes after oral administration of 10 mg metoclopramide or 2.5 mg bromocriptine. A period of 3 days intervened between testing each drug in the same individual. It was shown that basal prolactin levels in amyotrophic lateral sclerosis patients and the controls did not differ significantly, whereas in the metoclopramide stimulation test seven amyotrophic lateral sclerosis patients showed a very exaggerated response. The mean value of maximal prolactin increment was 1609.90% (SD 456) in comparison with the control group 638.3% (SD 89.7) (p less than 0.01). In the bromocriptine inhibition test the mean value of maximal prolactin percentage decrement was 50.4% (SD 6.1) in amyotrophic lateral sclerosis and 66.5% (SD 5.3) in the controls and this difference was statistically insignificant. These data suggest that exaggerated prolactin response to metoclopramide in amyotrophic lateral sclerosis may be a result of a decreased activity of central dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3404163      PMCID: PMC1033069          DOI: 10.1136/jnnp.51.5.643

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  16 in total

1.  Effects of prolactin and ergot alkaloids on the tubero-infundibular dopamine (DA) neurons.

Authors:  T Hökfelt; K Fuxe
Journal:  Neuroendocrinology       Date:  1972       Impact factor: 4.914

2.  Amyotrophic lateral sclerosis. A study of central monoamine metabolism and therapeutic trial of levodopa.

Authors:  J R Mendell; T N Chase; W K Engel
Journal:  Arch Neurol       Date:  1971-10

3.  Reduced lumbar cerebrospinal fluid corticotropin releasing factor (CRF) levels in amyotrophic lateral sclerosis.

Authors:  A Klimek; D Cieślak; J Szulc-Kuberska; H Stepien
Journal:  Acta Neurol Scand       Date:  1986-07       Impact factor: 3.209

Review 4.  Dopamine: a prolactin-inhibiting hormone.

Authors:  N Ben-Jonathan
Journal:  Endocr Rev       Date:  1985       Impact factor: 19.871

5.  The effect of metoclopramide, TRH and L-dopa on prolactin secretion in pituitary adenoma and in "functional" galactorrhoea syndrome.

Authors:  W Jeske
Journal:  Acta Endocrinol (Copenh)       Date:  1979-07

6.  A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease.

Authors:  S H Appel
Journal:  Ann Neurol       Date:  1981-12       Impact factor: 10.422

7.  [Serum prolactin level in basal conditions and after metoclopramide stimulation in women with galactorrhea and in patients with pituitary tumors].

Authors:  M Pawlikowski; J Komorowski; I Owczarczyk
Journal:  Endokrynol Pol       Date:  1983       Impact factor: 1.582

8.  Amyotrophic lateral sclerosis: alterations in neurotransmitter receptors.

Authors:  P J Whitehouse; J K Wamsley; M A Zarbin; D L Price; W W Tourtellotte; M J Kuhar
Journal:  Ann Neurol       Date:  1983-07       Impact factor: 10.422

9.  Epidermal growth factor in human cerebrospinal fluid: reduced levels in amyotrophic lateral sclerosis.

Authors:  D Cieślak; J Szulc-Kuberska; H Stepień; A Klimek
Journal:  J Neurol       Date:  1986-11       Impact factor: 4.849

Review 10.  Amyotrophic lateral sclerosis: Part 2. Etiopathogenesis.

Authors:  R Tandan; W G Bradley
Journal:  Ann Neurol       Date:  1985-10       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.